But exactly to the point. A BILLION dollar evaluation on a phase 2. Multikine is phase 3 with Sooo many potential indications.. $200 million is freaking blasphemy on our evaluation. We are twice what Peloton is and that in no bias is a generous statement in my mind. At 40 million shares we should bebat $50 a share when compared to them.. minimum....